אפטרדיי ישראל - עברית - Ministry of Health

אפטרדיי

trima israel pharmaceutical products maabarot ltd - levonorgestrel 1.5 mg - tablets - levonorgestrel - emergency contraceptive

מרסילון ישראל - עברית - Ministry of Health

מרסילון

organon pharma israel ltd., israel - desogestrel; ethinylestradiol - טבליה - desogestrel 150 mcg; ethinylestradiol 20 mcg - desogestrel - desogestrel - oral contraception

מרסילון ישראל - עברית - Ministry of Health

מרסילון

merck sharp & dohme israel ltd - desogestrel; ethinylestradiol - טבליה - desogestrel 150 mcg; ethinylestradiol 20 mcg - desogestrel - desogestrel - oral contraception

גינרה ישראל - עברית - Ministry of Health

גינרה

bayer israel ltd - ethinylestradiol; gestodene - טבליות מצופות - ethinylestradiol 0.03 mg; gestodene 0.075 mg - ethinylestradiol - ethinylestradiol - hormonal contraception.

זואלי ישראל - עברית - Ministry of Health

זואלי

merck sharp & dohme israel ltd - estradiol as hemihydrate 1.5 mg; nomegestrol acetate 2.5 mg - film coated tablets - estradiol - oral contraception

היקמטין 0.25 מג ישראל - עברית - Ministry of Health

היקמטין 0.25 מג

novartis israel ltd - topotecan as hydrochloride - קפסולות ג'לטין קשיחות - topotecan as hydrochloride 0.25 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.

ארומזין ישראל - עברית - Ministry of Health

ארומזין

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

סנדאימון   ניאורל   50 מג כמוסות ישראל - עברית - Ministry of Health

סנדאימון ניאורל 50 מג כמוסות

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

סנדאימון   ניאורל   100 מג כמוסות ישראל - עברית - Ministry of Health

סנדאימון ניאורל 100 מג כמוסות

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

רפמיון תמיסה ישראל - עברית - Ministry of Health

רפמיון תמיסה

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.